This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01342211
First received: April 25, 2011
Last updated: October 16, 2013
Last verified: October 2013
  Purpose
This study will investigate the effect of PF-04950615, a new investigational lipid lowering agent, on LDL-C and other lipids.

Condition Intervention Phase
Hypercholesterolemia Dyslipidemia Biological: Placebo Biological: PF-04950615 (RN316) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study To Assess The Efficacy, Safety, And Tolerability Of PF-04950615 (RN316)Following Multiple Intravenous Doses In Hypercholesterolemic Subjects On High Doses Of Atorvastatin, Rosuvastatin Or Simvastatin

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Observed mean percentage reduction from baseline in LDL-C [ Time Frame: Day 85 ]

Secondary Outcome Measures:
  • Proportion of subjects achieving a significant decrease in LDL C from baseline. [ Time Frame: Day 85 ]
  • Change and percentage change from baseline in other lipid parameters: total cholesterol, HDL C, non-HDL C, TG, ApoB, ApoA1 and Lpa. [ Time Frame: Day 85 ]
  • Incidence, severity and causal relationship of treatment emergent AEs (TEAEs). [ Time Frame: Day 141 ]
  • Incidence of abnormal and clinically relevant safety laboratories including clinical chemistry, hematology and coagulation assessments. [ Time Frame: Day 141 ]
  • Abnormal and clinically relevant changes in vital signs, BP, and ECG parameters. [ Time Frame: Day 141 ]
  • Incidence of anti-drug-antibodies. [ Time Frame: Day 141 ]

Enrollment: 93
Study Start Date: July 2011
Study Completion Date: July 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Treatment A Biological: Placebo
Intravenous placebo monthly during treatment phase.
Experimental: Treatment B Biological: PF-04950615 (RN316)
Intravenous 10mg/mL based on weight monthly during treatment phase.
Experimental: Treatment C Biological: PF-04950615 (RN316)
Intravenous 10mg/mL based on weight monthly during treatment phase.
Experimental: Treatment D Biological: PF-04950615 (RN316)
Intravenous 10mg/mL based on weight monthly during treatment phase.
Experimental: Treatment E Biological: PF-04950615 (RN316)
Intravenous 10mg/mL based on weight monthly during treatment phase.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • On a stable daily dose of atorvastatin, rosuvastatin or simvastatin.
  • Lipids meet the following criteria at screening and prior to dosing: Fasting LDL-C greater than 100 mg/dL and fasting TG less than 400 mg/dL

Exclusion Criteria:

  • History of a cardiovascular or cerebrovascular event or procedure during the past year.
  • Poorly controlled type 1 or type 2 diabetes mellitus.
  • Poorly controlled hypertension.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01342211

  Show 38 Study Locations
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT01342211     History of Changes
Other Study ID Numbers: B1481005
Study First Received: April 25, 2011
Last Updated: October 16, 2013

Keywords provided by Pfizer:
PF-04950615
RN316

Additional relevant MeSH terms:
Hypercholesterolemia
Dyslipidemias
Hyperlipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on August 18, 2017